Orano Med Inaugurates a New Lead-212-Based Radioligand Therapies Production Site

News, Featured

Orano Inaugurates a New Lead-212-Based Radioligand Therapies Production Site Earlier this October, Orano Med, a subsidiary of Orano (ENS Corporate Member), announced the inauguration of its ATLab (Alpha Therapy Laboratory) in Valenciennes, France. It is Europe’s first industrial-scale pharmaceutical facility dedicated to producing lead-212-based radioligand therapies. Lead-212 is increasingly recognised for its role in targeted alpha therapies (TATs),…

orano

Orano Joins ENS As A New Corporate Member

News

Orano Joins ENS As A New Corporate Member Following the approval of the ENS General Assembly, we are glad to announce that Orano has joined the European Nuclear Society as a new Corporate Member, effective 9th June 2026. Orano is a French multinational company operating across the nuclear fuel cycle and providing products and services to…